RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine

BACKGROUND: The usefulness of ribonucleotide reductase catalytic subunit M1 (RRM1) for predicting the therapeutic effects of gemcitabine-containing chemotherapy in patients with non-small cell lung cancer (NSCLC) remains controversial. RRM1-positive patients show unique clinicopathological features....

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ying, Huang, Ying, Chen, Dong-Ming, Wu, Chao, Leng, Qiu-Ping, Wang, Wen-Yi, Deng, Ming-Qin, Zhao, Yan-Xia, Yang, Xiao-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135431/
https://www.ncbi.nlm.nih.gov/pubmed/30237724
http://dx.doi.org/10.2147/OTT.S162667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135431/
https://www.ncbi.nlm.nih.gov/pubmed/30237724
http://dx.doi.org/10.2147/OTT.S162667

Ejemplares similares